Clinical Update Promising Results From First-of-Its-Kind CRISPR Trial To Treat Solid Tumours
Last week, PACT Pharma shared results from the first clinical trial using CRISPR to direct patients’ immune cells to treat solid tumours. The findings, which were published in an unedited manuscript in Nature, provide early proof-of-concept that patient immune cells can be reprogrammed to attack their own cancer. The results were also presented on the same day at the Society for Immunotherapy of Cancer meeting in Boston, Massachusetts, U.S. By: Karen O'Hanlon Cohrt - Nov. 16, 2022
Overview: Diseases That Gene Editors Potentially Could Cure
In this post, we introduce our CMN disease overview, which will provide information on all the diseases that are targeted by gene-editing therapies involving CRISPR, prime editors, base editors, ZFNs, TALENs, Cas-CLOVER, MegaTAL and MegaNucleases.
Engineering Approaches to Improve CRISPR Technologies Tuesday Dec. 6, 2022 | 3:00 pm – 4:30 pm CET
Speaker: Ben Kleinstiver, Ass. Prof.,Mass General Hospital and Harvard Medical School, Boston, USA
